工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cell delivery devices for cancer immunotherapy.
Cell delivery devices for cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
利用同种异体或自体免疫细胞的过继细胞疗法(ACT)在靶向癌症治疗中具有巨大前景。尽管ACT在治疗血液系统恶性肿瘤方面取得了巨大成功,但通过静脉输注免疫细胞来根除实体瘤的疗效仍然有限。随着癌症免疫治疗技术的不断拓展,人们探索了新型递送策略,通过创新给药途径、维持细胞活力以及使肿瘤微环境正常化,来提高过继转移细胞治疗实体瘤的治疗效力。在本综述中,总结了多种用于细胞递送的装置。同时讨论了用于癌症免疫治疗的细胞递送装置的前景与挑战。
Adoptive cell therapy (ACT) that leverages allogeneic or autologous immune cells holds vast promise in targeted cancer therapy. Despite the tremendous success of ACT in treating hematopoietic malignancies, its efficacy is limited in eradicating solid tumors via intravenous infusion of immune cells.
With the extending technology of cancer immunotherapy, novel delivery strategies have been explored to improve the therapeutic potency of adoptively transferred cells for solid tumor treatment by innovating the administration route, maintaining the cell viability, and normalizing the tumor microenvironment. In this review, a variety of devices for cell delivery are summarized. Perspectives and challenges of cell delivery devices for cancer immunotherapy are also discussed.
MEMBER ACCOUNT
登录成功会直接打开下一页。